The Refinancing Cliff: Why PE Portfolios Are More Exposed to 2026–2028 Debt Maturities Than Anyone Is Admitting

Somewhere in the back of nearly every GP's quarterly portfolio review is a slide that deserves far more attention than it typically receives. It shows debt maturity schedules — the dates by which leveraged loans and high-yield bonds must be refinanced or repaid. For vintage years 2019 through 2022, those dates are converging on a narrow and increasingly uncomfortable window: 2026 to 2028.

The problem is not simply that debt is coming due. Debt always comes due. The problem is that the rate environment in which much of this debt was originally structured has been replaced by one that looks nothing like it. When sponsors underwrote those deals, the cost of capital was near historic lows. The refinancing assumptions baked into their models reflected a world that no longer exists — and many firms have been slow to revise them.

How the Assumptions Got Embedded

Between 2019 and 2022, the private equity market operated under conditions that, in retrospect, were extraordinary. The Federal Reserve's accommodative posture kept borrowing costs suppressed, covenant-lite structures became standard, and leverage multiples expanded accordingly. Sponsors grew comfortable layering seven or eight turns of EBITDA onto acquisitions because the debt service math worked — just barely — at prevailing rates.

The underlying assumption in most of those models was not that rates would stay low forever. It was more subtle than that: sponsors assumed that by the time refinancing was required, rates would have normalized to something manageable. A modest uptick was priced in. A sustained high-rate environment was not.

The Federal Reserve's rate-hiking cycle that began in March 2022 and pushed the federal funds rate to its highest level in over two decades has not fully reversed. While markets have periodically priced in aggressive cuts, the pace of easing has remained slower than anticipated. For PE firms sitting on portfolios with 2026 or 2027 maturities, that lag is no longer an abstraction. It is a capital structure problem with a fixed deadline.

The Modeling Gap Nobody Wants to Discuss

To understand why this risk is being underestimated, it helps to understand how refinancing scenarios are typically modeled at the portfolio company level. Most GP financial models include a refinancing assumption — but it is often a static one, built on a projected rate at a projected point in time. When that projection is wrong by two or three hundred basis points, the effect on debt service coverage and free cash flow can be severe.

The more significant failure, however, is not the rate assumption itself. It is the absence of stress-testing around it. In many cases, refinancing risk does not appear as a discrete line item in portfolio monitoring dashboards. It sits inside the capital structure section, reviewed periodically, but rarely stress-tested against scenarios where rates remain elevated and credit markets tighten simultaneously.

This creates a blind spot. A portfolio company with $400 million in leveraged loans maturing in early 2027 may look perfectly healthy on an EBITDA basis today. But if refinancing that debt at current market rates adds $18 to $22 million in annual interest expense, the free cash flow picture changes materially — and with it, the company's ability to service debt, fund growth, or attract a buyer at a reasonable multiple.

Forced Decisions and Constrained Options

For portfolio companies with thin coverage ratios and near-term maturities, the menu of options is narrowing. The cleanest path — refinancing at par with a new term loan — remains available for companies with strong credit profiles and sponsor support. But for the broader population of leveraged buyouts from the 2020–2022 vintage, particularly those in sectors that have underperformed post-acquisition, the math is harder.

Some firms are already executing liability management transactions: amend-and-extend negotiations with existing lenders, private credit refinancings that provide breathing room at a higher cost, or equity injections from sponsors willing to protect their basis. Each of these carries its own trade-offs. Amend-and-extend deals often require consent thresholds that are difficult to achieve across fragmented loan syndicates. Private credit refinancings resolve the maturity issue but can push all-in yields to levels that make exit multiples nearly impossible to achieve. Equity injections protect the asset but dilute returns and consume dry powder that sponsors had earmarked for new investments.

Then there is the option that nobody wants to discuss openly: the forced asset sale. A portfolio company that cannot refinance its debt on acceptable terms, cannot attract a strategic buyer at a price that clears the capital structure, and whose sponsor lacks the willingness or capacity to inject additional equity faces a constrained set of outcomes — none of them good for LP returns.

The Firms That Are Actually Preparing

Not every GP is waiting for the problem to arrive. A subset of firms — particularly those with dedicated portfolio operations teams and active treasury management functions — began addressing maturity risk in 2023 and early 2024, well before the deadlines became urgent.

The strategies vary. Some sponsors have systematically extended maturities across their portfolios by refinancing into longer-dated instruments even at higher current rates, accepting near-term cash flow pressure in exchange for optionality. Others have worked with portfolio company management teams to accelerate EBITDA improvement initiatives specifically to strengthen refinancing leverage with lenders. A smaller group has been quietly marketing assets with 2026 maturities now, accepting exit timing that is earlier than ideal rather than risk a distressed process later.

What distinguishes these firms is not superior foresight so much as a willingness to act on information that was available to everyone. The maturity schedules were never hidden. The rate environment has been telegraphed for over two years. The gap between awareness and action is largely a function of institutional incentive structures — specifically, the tendency to defer difficult decisions when current valuations remain defensible and LP pressure has not yet materialized.

What LPs Should Be Asking

For limited partners reviewing their GP relationships, the refinancing wall is a legitimate area of inquiry that has not yet received the scrutiny it warrants. The questions are straightforward: What percentage of the portfolio has debt maturing before the end of 2028? What are the coverage ratios at current market rates, not the rates assumed at origination? Which assets have already been refinanced, and on what terms? Which have not, and why?

GPs that cannot answer these questions with specificity are either not tracking the risk or are reluctant to surface it. Neither is a satisfying answer for an institutional investor trying to assess the durability of its private equity allocation.

The Reckoning Ahead

The private equity industry has navigated rate cycles before. It has absorbed credit crunches, restructured portfolios, and found ways to protect returns under pressure. There is no reason to assume that the 2026–2028 maturity window will produce a systemic crisis rather than a manageable period of elevated stress.

But manageable stress and invisible risk are not the same thing. The firms that treat the refinancing wall as a known variable to be engineered around — rather than a problem that might solve itself if rates cooperate — are the ones most likely to emerge from this cycle with their portfolios and their LP relationships intact. The ones still hoping for the Fed to bail them out may find that hope is not a capital structure.